Satellos Bioscience Advances DMD Drug Trials with Positive Financial Outlook

Satellos Bioscience ( (TSE:MSCL) ) just unveiled an announcement.

Satellos Bioscience has completed enrollment for its Phase 1b trial of SAT-3247 in adult patients with Duchenne muscular dystrophy, with data expected in Q2 2025. The company has secured regulatory approval for a long-term follow-up study and plans to initiate a Phase 2 trial in pediatric patients. Financially, Satellos reported a net loss of $6.1 million for Q1 2025, with $41.2 million in funds available to support its operations and upcoming trials.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.

To see Spark’s full report on TSE:MSCL stock, click here.

More about Satellos Bioscience

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing medicines to treat degenerative muscle diseases. The company is advancing its novel drug, SAT-3247, targeting Duchenne muscular dystrophy (DMD) and is positioned to conduct further clinical trials to assess its efficacy and safety.

Average Trading Volume: 149,363

Technical Sentiment Signal: Sell

Current Market Cap: C$98.16M

See more insights into MSCL stock on TipRanks’ Stock Analysis page.